Sanofi-Aventis (SNY) On the Prowl For A Mega-Deal In the U.S.?
More News related to AGN
- Spectrum Pharma (SPPI) and Handok Pharma Announce Plans for Apaziquone Development in South Korea
- 2010 IR Global Rankings: Invitation for Investors and Analysts Vote for Companies with the Best IR Program and for the Best IR Officer
- Spectrum Pharma (SPPI) To Collaborate with Nippon Kayaku to Develop and Commercialize Apaziquone in Asia
- The Lowe Law Firm Files Suit over Alleged Botox Overdose
- Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution
More News related to AMGN
- New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists
- Amgen Highlights Data to be Presented at ASH
- Beacon Equity Issues Technical Trading Overview for NexMed Inc.
- Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards
- Amgen to Present at Lazard Capital Healthcare Conference
More News related to BIIB
- Facet Biotech Advises Stockholders to Take No Action in Response to Revised Biogen Idec Tender Offer
- Biogen (BIIB) Boosts Bid for Facet Biotech (FACT) to $17.50/Share in Cash
- Biogen Idec Increases Offer to Acquire Facet Biotech to $17.50 Per Share in Cash; Sends Letter to Facet Biotech Stockholders Describing Its Best-and-Final Offer
- InvestorSoup.com Issues Technical Trading Outlook for ARCA biopharma Inc.
- Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia
More News related to Insiders' Blog
- Interesting Call Buying In Research In Motion (RIMM)
- Broadpoint.AmTech Reiterates a 'Buy' on Marvell Technology (MRVL); Raises Estimates & PT
- Unemployment Data Brings Hope: Art Hogan Weighs In
- Brean Murray Maintains a 'Buy' on athenahealth (ATHN); Lofty Valuation Surpassed Only by Lofty Goals
- Benchmark Raises American Tower's (AMT) Price Target to $50 on Strong Tower Demand
According to reports the Wall Street Journal's Deal Journal, Sanofi-Aventis (NYSE: SNY) is on the prowl for a mega-deal in the U.S, citing reports in French business newspaper Les Echos.
Deal Journal said one obvious takeover target is Bristol-Myers Squibb (NYSE: BMY), since the two companies already have an existing partnership developing blood clot drug Plavix. Amgen (Nasdaq: AMGN) is seen as another possible takeover candidate.
European bankers said a deal to acquire Amgen could jeopardize Sanofi’s investment-grade credit rating.
Other more likely takeover targets include botox-maker Allergan (NYSE: AGN) or biotech company Biogen Idec (Nasdaq: BIIB), where activist investor Carl Icahn just won two board seats.
Link to WSJ Deal Journal Article
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
Insiders' BlogRumors
Stocks Mentioned
+0.41
-0.02Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
